The impact of centralised care of younger AML patients on treatment results: a retrospective analysis of real-world data from a national population-based registry

• Authors: SEMERAD Lukas; SUSTKOVA Zuzana; CETKOVSKY Petr; JINDRA Pavel; KORISTEK Zdenek; NOVAK Jan; RACIL Zdenek; SZOTKOWSKI Tomas; WEINBERGEROVA Barbora; ZAK Pavel; POSPÍŠIL Zdeněk; BARANOVA Jana; MAYER Jiri
• Year of publication: 2021
• Type: Article in Periodical
• Magazine / Source: Acta Oncologica
• MU Faculty or unit: Faculty of Science
• Web: https://www.tandfonline.com/doi/full/10.1080/0284186X.2021.1917002
• Doi: http://dx.doi.org/10.1080/0284186X.2021.1917002
• Keywords: ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; HOSPITAL VOLUME; MORTALITY; CHEMOTHERAPY; OUTCOMES
• Description: The care for younger patients with acute myeloid leukaemia (AML) requires fully equipped medical facilities that have routine experience with the management of this aggressive disorder. Two independent analyses of real-world data from the United States (US) have showed a lower early mortality after an intensive chemotherapy when the patients are treated in high-volume centres or in National Cancer Institution-Designated Cancer Centres (NCI-CC) compared to the treatment in low-volume or in non-NCI-CC centres [1,2].